Abstracts

172 – Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation

Background People with HIV (PWH) are at higher risk for visceral adiposity and enhanced inflammation, and lower neurocognitive function when compared to controls without HIV. In a recent randomized placebo-controlled clinical trial of the GLP1 receptor agonist semaglutide, we demonstrated that PWH with lipohypertrophy had a decrease in weight, visceral adipose tissue, and in several…

171 – Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV

Background Alzheimer’s disease (AD) is the leading cause of dementia worldwide, and accurate diagnosis is crucial, including for people with HIV (PWH). Blood-based biomarkers for AD offer a promising, low-cost, non-invasive diagnostic alternative, but data are limited in PWH. Our study measured phosphorylated tau 217 (p-tau217)–the only blood-based biomarker currently recommended for diagnosing AD–and assessed…

159 – Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx

Background ACTG A5418/STOMP is a phase 3 randomized placebo-controlled double-blind trial evaluating the efficacy of tecovirimat in people with mpox.  It includes an open-label arm for people <18 years, pregnant or breastfeeding, with severe immune suppression, or protocol-defined severe disease. We analyzed host and disease factors associated with clinical mpox resolution and mpox DNA clearance…

153 – Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor

Background New long-acting antiretroviral therapy (ART) regimens are needed to expand treatment choices for people living with HIV-1. VH4011499 (VH-499) is a new HIV-1 capsid inhibitor in development as a long-acting antiretroviral agent for the treatment and prevention of HIV-1. Here, we present antiviral effect, pharmacokinetics, safety, and tolerability data for VH-499 from a proof-of-concept,…

152 – Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor

Background New long-acting antiretroviral therapy (ART) regimens are needed to expand treatment choices for people living with HIV-1. VH4524184 (VH-184) is a third-generation integrase strand transfer inhibitor (INSTI) with an enhanced in vitro resistance profile compared with second-generation INSTIs being developed as a long-acting antiretroviral agent for the treatment of HIV-1. Here, we present data…

101 – BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence

Background Tissue resident memory T cells (TRMs) protect the gut mucosal barrier against microbial invasion by exerting rapid and localized effector functions while restraining excessive inflammation. Yet, pathogens can evade immune clearance and persist. The gut is a major HIV-1 reservoir in people living with HIV-1 (PLWH). However, given the rarity of HIV-1-infected cells (<0.1%) and the…